Woodward DF - Search Results

1

The affinity, intrinsic activity and selectivity of a structurally novel EP₂ receptor agonist at human prostanoid receptors.

Coleman RA, Woodrooffe AJ, Clark KL, Toris CB, Fan S, Wang JW, Woodward DF. Coleman RA, et al. Among authors: woodward df. Br J Pharmacol. 2019 Mar;176(5):687-698. doi: 10.1111/bph.14525. Epub 2019 Jan 4. Br J Pharmacol. 2019. PMID: 30341781 Free PMC article.

2

Prostanoid Receptor Antagonist Effects on Intraocular Pressure, Supported by Ocular Biodisposition Experiments.

Woodward DF, Wenthur SL, Rudebush TL, Fan S, Toris CB. Woodward DF, et al. J Ocul Pharmacol Ther. 2016 Nov;32(9):606-622. doi: 10.1089/jop.2016.0069. Epub 2016 Oct 20. J Ocul Pharmacol Ther. 2016. PMID: 27763812

3

A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method.

Woodward DF, Wang JW, Coleman RA, Woodrooffe AJ, Clark KL, Stamer WD, Tao G, Fan S, Toris CB. Woodward DF, et al. J Ocul Pharmacol Ther. 2019 Jun;35(5):265-277. doi: 10.1089/jop.2018.0126. Epub 2019 Apr 25. J Ocul Pharmacol Ther. 2019. PMID: 31025909

4

Roles of affinity and lipophilicity in the slow kinetics of prostanoid receptor antagonists on isolated smooth muscle preparations.

Jones RL, Woodward DF, Wang JW, Clark RL. Jones RL, et al. Among authors: woodward df. Br J Pharmacol. 2011 Feb;162(4):863-79. doi: 10.1111/j.1476-5381.2010.01087.x. Br J Pharmacol. 2011. PMID: 20973775 Free PMC article.

5

Prostaglandin E2-Glyceryl Ester: In Vivo Evidence for a Distinct Pharmacological Identity from Intraocular Pressure Studies.

Woodward DF, Poloso NJ, Wang JW. Woodward DF, et al. J Pharmacol Exp Ther. 2016 Aug;358(2):173-80. doi: 10.1124/jpet.116.232512. Epub 2016 May 23. J Pharmacol Exp Ther. 2016. PMID: 27217589

6

Antiglaucoma EP₂ Agonists: A Long Road That Led Somewhere.

Woodward DF, Wang JW, Stamer WD, Lütjen-Drecoll E, Krauss AH, Toris CB. Woodward DF, et al. J Ocul Pharmacol Ther. 2019 Nov;35(9):469-474. doi: 10.1089/jop.2019.0041. Epub 2019 Jul 19. J Ocul Pharmacol Ther. 2019. PMID: 31329508 Review.

7

Effect of the Antiglaucoma Agent JV-GL1 and Related Compounds in the Canine Eye.

Woodward DF, Coleman RA, Woodrooffe AJ, Spada CS, Wang JW. Woodward DF, et al. J Ocul Pharmacol Ther. 2020 Oct;36(8):636-648. doi: 10.1089/jop.2020.0033. Epub 2020 Jul 8. J Ocul Pharmacol Ther. 2020. PMID: 32640926

8

Prostanoid receptor assays.

Chen J, Woodward DF, Coleman RA, Jones RL, Lydford SJ. Chen J, et al. Among authors: woodward df. Curr Protoc Pharmacol. 2001 Nov;Chapter 4:Unit4.18. doi: 10.1002/0471141755.ph0418s14. Curr Protoc Pharmacol. 2001. PMID: 21959759

9

The role of EP₂ receptors in mediating the ultra-long-lasting intraocular pressure reduction by JV-GL1.

Bertrand JA, Woodward DF, Sherwood JM, Wang JW, Overby DR. Bertrand JA, et al. Among authors: woodward df. Br J Ophthalmol. 2021 Nov;105(11):1610-1616. doi: 10.1136/bjophthalmol-2020-317762. Epub 2020 Nov 25. Br J Ophthalmol. 2021. PMID: 33239414 Free PMC article.

10

Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow.

Woodward DF, Nilsson SF, Toris CB, Kharlamb AB, Nieves AL, Krauss AH. Woodward DF, et al. Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3320-8. doi: 10.1167/iovs.08-3031. Epub 2009 Feb 21. Invest Ophthalmol Vis Sci. 2009. PMID: 19234340

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

182 results

Search Page

Filters